Lipocine Inc. Files 8-K
Ticker: LPCN · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, routine-update
TL;DR
Lipocine filed an 8-K, looks like standard procedure, no major news.
AI Summary
Lipocine Inc. filed an 8-K on February 6, 2025, reporting other events and financial statements. The filing does not contain specific details about new material events, acquisitions, or financial results, but rather serves as a procedural update and filing of exhibits.
Why It Matters
This 8-K filing by Lipocine Inc. indicates a routine update or submission of required documents to the SEC, without disclosing new material information that would immediately impact the company's stock.
Risk Assessment
Risk Level: low — The filing is a routine 8-K submission and does not contain any new material information that would inherently increase risk.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- 001-36357 (company) — Commission File Number
- February 6, 2025 (date) — Date of Report
- 675 Arapeen Drive, Suite 202 (address) — Principal Executive Offices
- Salt Lake City, Utah 84108 (address) — Principal Executive Offices
- (801) 994-7383 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Lipocine Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of February 6, 2025.
Does this filing disclose any new material events or financial results for Lipocine Inc.?
Based on the provided text, this filing does not explicitly disclose any new material events or specific financial results; it appears to be a procedural filing.
What is Lipocine Inc.'s Commission File Number?
Lipocine Inc.'s Commission File Number is 001-36357.
Where are Lipocine Inc.'s principal executive offices located?
Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
When was this 8-K report filed by Lipocine Inc.?
This 8-K report was filed on February 6, 2025.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2025-02-06 09:30:10
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 43KB
- form8-k_001.jpg (GRAPHIC) — 4KB
- ex99-1.htm (EX-99.1) — 20KB
- 0001493152-25-005108.txt ( ) — 249KB
- lpcn-20250206.xsd (EX-101.SCH) — 3KB
- lpcn-20250206_lab.xml (EX-101.LAB) — 33KB
- lpcn-20250206_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: February 6, 2025 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer